Wu J, Zhao X, Chen H, Zhu S, et al. Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated meta-analysis of randomized controlled trials. J Diabetes Complications 2022;36:108352.
PMID: 36370667